2898 — Sunho Biologics Income Statement
0.000.00%
HealthcareMid Cap
- HK$6.58bn
- HK$6.56bn
- CNY56.13m
Annual income statement for Sunho Biologics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PRESS |
Standards: | IFRS | IFRS | — |
Status: | Final | Final | Final |
Revenue | |||
Total Revenue | 0 | 0 | — |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Depreciation and Amortization | |||
Unusual Expense / Income | |||
Other Operating Expenses | |||
Total Operating Expenses | 46.9 | 132 | 79 |
Operating Profit | -46.9 | -132 | -79 |
Total Net Non Operating Interest Income / Expense | |||
Net Income Before Taxes | -52 | -133 | -80 |
Provision for Income Taxes | |||
Net Income After Taxes | -52 | -133 | -80 |
Net Income Before Extraordinary Items | |||
Net Income | -52 | -133 | -80 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | -52 | -133 | -80 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | -0.403 | -0.722 | -0.42 |